Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The FDA cleared Viatris inc (NASDAQ:VTRS) - Biocon Biologics' Semglee insulin glargine-yfgn injection as a biosimilar.
- Semglee indicates controlling high blood sugar in adults with type 2 diabetes and pediatric patients with type 1 diabetes.
- The FDA approved Semglee as the first interchangeable biosimilar product under the 351(k) regulatory pathway.
- The product is sold in a pre-filled disposable pen.
- According to the release, the interchangeable product will allow for the substitution of Semglee for the reference product, Lantus, at the pharmacy counter. It will be introduced before the end of 2021.
- The Company is eligible for 12 months of exclusivity before the FDA can approve another biosimilar interchangeable to Lantus.
- Price Action: VTRS shares are up 3.87% at $14.78 during the premarket session on the last check Thursday.
- Related content: Benzinga's Full FDA Calendar.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!